NeuroOne Medical Technologies Corp 美股招股说明书（2026-06-12版）

(To the Prospectus Supplements dated April 3, 2025, August 16, 2024 and August 15, 2025)(To the Prospectus dated August 16, 2024) NeuroOne Medical Technologies Corporation $13,400,000 Common Stock This prospectus supplement supplements the prospectus supplements dated August 16, 2024, April 3, 2025 and August 15,2025 (the “Prior ATM Prospectus Supplement”), to the prospectus dated August 16, 2024 (the “Base Prospectus” and, together withthe Prior ATM Prospectus Supplement, the “Prior Prospectus”), relating to the offer and sale of shares of our common stock, par value$0.001 per share, through JonesTrading Institutional Services LLC (“Jones”), as sales agent, in “at the market offerings” (as defined inRule 415 promulgated under the Securities Act of 1933, as amended) pursuant to a Capital on Demand™ Sales Agreement (the “SalesAgreement”), dated December 21, 2022, that we entered into with Jones. As of the date hereof, we have sold an aggregate of This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference to the PriorProspectus in all respects, except to the extent that the information presented herein supersedes the information contained in the PriorProspectus. This prospectus supplement is not complete without, and may only be delivered or used in connection with, the Prior Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “NMTC.” On June 11, 2026, the lastreported sale price of our common stock on Nasdaq was $3.24 per share. The aggregate market value of our outstanding common stock held by non-affiliates pursuant to General Instruction I.B.6 ofForm S-3 was approximately $41.48 million, which was calculated based on 8,117,474 shares of our outstanding common stock heldby non-affiliates and a price of $5.11 per share, which was the price at which our common stock was last sold on the Nasdaq Capital Investing in our securities involves a high degree of risk. See “Risk Factors” in the Original Prospectus and documentsincorporated therein by reference for a discussion of such risk factors, which factors should be read carefully in connection Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any Prospectus supplement dated, June 12, 2026